Impact BioMedical, INC. Selling, General and Administrative Expense
Impact BioMedical, INC. (IBO) reported Selling, General and Administrative Expense of $167.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-07
- Impact BioMedical, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $167.00K, a 32.11% decline year-over-year.
- Impact BioMedical, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $1.62M, a 553.23% increase year-over-year.
- Impact BioMedical, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $118.00K, a 59.86% decline year-over-year.
- Impact BioMedical, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $261.00K, a 97.73% increase year-over-year.
- Impact BioMedical, INC. selling, general and administrative expense for fiscal 2025 was $873.00K, a 21.59% increase from fiscal 2024.
- Impact BioMedical, INC. selling, general and administrative expense for fiscal 2024 was $718.00K, a 127.94% increase from fiscal 2023.
- Impact BioMedical, INC. selling, general and administrative expense for fiscal 2023 was $315.00K, a 3.08% decline from fiscal 2022.
- Impact BioMedical, INC. selling, general and administrative expense for fiscal 2022 was $325.00K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $167.00K 10-Q · filed 2026-08-07 | $1.79M 10-Q · filed 2026-08-07 | $1.91M derived: sum of 3 quarters · filed 2026-08-07 | $2.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.62M 10-Q · filed 2026-05-12 | $1.74M derived: sum of 2 quarters · filed 2026-05-12 | $2.00M derived: sum of 3 quarters · filed 2026-05-12 | $2.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $379.00K derived: sum of 2 quarters · filed 2026-03-11 | $625.00K derived: sum of 3 quarters · filed 2026-08-07 | $873.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $261.00K 10-Q · filed 2025-11-07 | $507.00K derived: sum of 2 quarters · filed 2026-08-07 | $755.00K 10-Q · filed 2025-11-07 | $1.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $246.00K 10-Q · filed 2026-08-07 | $495.00K 10-Q · filed 2026-08-07 | $788.00K derived: sum of 3 quarters · filed 2026-08-07 | $920.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $248.00K 10-Q · filed 2026-05-12 | $542.00K derived: sum of 2 quarters · filed 2026-05-12 | $674.00K derived: sum of 3 quarters · filed 2026-05-12 | $819.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $426.00K derived: sum of 2 quarters · filed 2026-03-11 | $571.00K derived: sum of 3 quarters · filed 2026-03-11 | $718.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $132.00K 10-Q · filed 2025-11-07 | $277.00K derived: sum of 2 quarters · filed 2025-11-07 | $424.00K 10-Q · filed 2025-11-07 | $558.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $145.00K 10-Q · filed 2025-08-14 | $292.00K 10-Q · filed 2025-08-14 | $426.00K derived: sum of 3 quarters · filed 2025-08-14 | $527.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $148.00K 10-Q · filed 2025-05-14 | $281.00K derived: sum of 2 quarters · filed 2025-05-14 | $382.00K derived: sum of 3 quarters · filed 2025-05-14 | $423.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $234.00K derived: sum of 2 quarters · filed 2025-03-28 | $275.00K derived: sum of 3 quarters · filed 2025-03-28 | $315.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $101.00K 10-Q · filed 2024-11-12 | $142.00K derived: sum of 2 quarters · filed 2024-11-12 | $182.00K 10-Q · filed 2024-11-12 | $221.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $41.00K 10-Q · filed 2024-08-13 | $81.00K 10-Q · filed 2024-08-13 | $120.00K derived: sum of 3 quarters · filed 2024-08-13 | $210.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $40.00K 10-Q · filed 2024-05-10 | $79.00K derived: sum of 2 quarters · filed 2024-05-10 | $169.00K derived: sum of 3 quarters · filed 2024-05-10 | $227.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $129.00K derived: sum of 2 quarters · filed 2024-02-20 | $187.00K derived: sum of 3 quarters · filed 2024-02-20 | $325.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | $90.00K 10-Q · filed 2023-11-13 | $148.00K derived: sum of 2 quarters · filed 2023-11-13 | $286.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $58.00K 10-Q · filed 2023-10-05 | $168.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |